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In the adult mammalian subventricular zone (SVZ), GFAP-positive neural stem cells (NSCs) generate neuroblasts that migrate tangen-
tially along the rostralmigratory stream (RMS) toward the olfactory bulb (OB). In themouse brain, we found that the plasticity inhibitors
Nogo-AandNogo receptor 1 (NgR1) aredifferentially expressed in theSVZ–OBsystem, inwhichNogo-A identifies immatureneuroblasts
and NgR1 germinal astrocytes. We therefore examined the role of Nogo-A and NgR1 in the regulation of neurogenesis. Pharmacological
experiments show that Nogo-66/NgR1 interaction reduces the proliferation of NSCs. This is consistent with a negative-feedback loop, in
which newly generated neurons modulate cell division of SVZ stem cells. Moreover, the Nogo-A–20 domain promotes neuroblast
migration toward the OB through activation of the Rho/ROCK (Rho-associated, coiled-coil containing protein kinase) pathway, without
the participation of NgR1. Our findings reveal a new unprecedented function for Nogo-A and NgR1 in the homeostatic regulation of the
pace of neurogenesis in the adult mouse SVZ and in the migration of neuroblasts along the RMS.
Introduction
Two decades of research have established a clear role for Nogo-A
and its receptor NgR1 in neuritic growth control in the mature
CNS, including the restriction of structural and synaptic plastic-
ity and the stabilization of connections (Buffo et al., 2000; Lee et
al., 2008; Raiker et al., 2010; Schwab 2010; Zagrebelsky et al.,
2010; Delekate et al., 2011). Although the bulk of Nogo-A expres-
sion is found in oligodendrocytes, its receptor NgR1 is primarily
expressed by different subpopulations of mature neurons (Wang
et al., 2002; Fischer et al., 2004).
However, both Nogo-A and NgR1 have been found in other
neural cell types, including progenitors during development
(Mingoranceet al., 2004;Mathis et al., 2010),neurosphere cells (Ma-
this et al., 2010), astrocytes (Wang et al., 2002;Mingorance-LeMeur
et al., 2007), and human astrocytoma and glioma cells (Cheung et
al., 2009; Xiong et al., 2012), suggesting additional functions for
this pathway. For instance, Nogo-A and NgR1 have been impli-
cated in neurosphere cell proliferation (Li et al., 2011), differen-
tiation (Wang and Zhu, 2008; Lo¨o¨v et al., 2012), and control of
tumormalignancy (Liao et al., 2004; Cheung et al., 2009; Xiong et
al., 2012). The latter findings point to the participation of Nogo-
A/NgR1 signaling in the regulation of other aspects of growth,
such as tissue expansion or turnover by cell proliferation.
To address this hypothesis, we studied the expression and
function of Nogo-A and NgR1 in the adult germinal zone resid-
ing in the lateral wall (LW) of the lateral ventricles [subventricu-
lar zone (SVZ)]. Here, neural stem cells (NSCs) with astrocytic
features generate intermediate progenitors giving rise to neuro-
blasts that migrate to the olfactory bulb (OB) along the rostral
migratory stream (RMS) (Kriegstein and Alvarez-Buylla, 2009;
Ihrie and Alvarez-Buylla, 2011). Using pharmacological ap-
proaches along with in vitro and in vivo experiments, we found
that Nogo-A/NgR1 signaling regulates the pace of neuronal neo-
generation by reducing NSC proliferation. We also provide evi-
dence that neuroblast migration to the OB is supported by the
activity of the Nogo-A–20 domain, independently of NgR1.
Materials andMethods
Animals, surgical procedures, and in vivo treatments. Experiments were
performed on different mouse lines, including C57BL/6 mice,
GLAST::CreErt2;R26R (Mori et al., 2006), and hGFAP::GFP (Zhuo et al.,
1997) animals. Adult male mice (2–4 months of age) were used unless
differently stated. Surgical procedures and perfusions were performed
under deep general anesthesia [100 mg/kg ketamine (Ketavet; Bayern)
and 5 mg/kg xylazine (Rompun; Bayer)]. The experimental plan was
designed according to the guidelines of the National Institutes of Health,
the European Communities Council (86/609/EEC), and the Italian law
for care and use of experimental animals (DL116/92). It was also ap-
proved by the ItalianMinistry ofHealth and the Bioethical Committee of
the University of Turin.
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Mice (GLAST::CreErt2;R26R) received tamoxifen dissolved in corn oil
to induce Cre activity and -galactosidase (-gal) reporter expression
(one administration of 5 mg each by oral gavage for 2 d) before treat-
ment. For acute injections, neutralizing peptide 1–40 (NEP1–40) antag-
onist (500MNEP1–40 in 97.5%PBS plus 2.5%DMSO; Sigma-Aldrich)
(GrandPre´ et al., 2002) or vehicle solution (97.5%PBSplus 2.5%DMSO)
were pressure injected into the left cerebral ventricle (coordinates relative
to bregma: anterior, 0; lateral, 1mm; depth, 1.8mm). Over a period of 20
min, 1l was injected. Alternatively, osmoticminipumps (Alzet osmotic
pumps 1007D) were implanted at the same coordinates to deliver
NEP1–40 peptide, vehicle solution, Nogo-A–20 [11C7, 0.5 mg/ml in
saline; raised against an 18-aa peptide in the most active region (20) of
Nogo-A; kindly supplied by Novartis Pharma; Oertle et al., 2003] or
control (mouse anti-human IgG; Jackson ImmunoResearch) antisera.
Choroid plexi (CPs) were dissected from the LWs of postnatal wild-type
mice and grafted according to Sawamoto et al. (2006) to inhibit cell
migration toward the OB. Animals were killed at 3 d after injection or at
7 or 10 d after minipump implantation.
Proliferation, fate analysis, and immunohistochemistry. To examine cell
proliferation, we used the thymidine analog 5-bromo-2-deoxyuridine
(BrdU; Sigma-Aldrich), which is incorporated in the DNA during the S
phase of the cell cycle and remains in the DNA even when the cell has
exited the active phases of the cells cycle. Depending on treatment, BrdU
tagging is suitable for detecting activemitosis, cells that have proliferated
over a certain time window, or cells that have exited the cell cycle (Boda
et al., 2011). In some experiments, BrdU was administered as a single
pulse (50 mg/kg, i.p., in saline) at either the moment of minipump im-
plantation or antagonist injection. In some cases, multiple BrdU injec-
tions were required to increase the probability for detection of NSC
divisions. Active proliferation was revealed by expression of theM-phase
marker phospho-histone H3 (Ph3) or Ki67 (an antigen present in the
S-to-M phases of the cell cycle; Boda et al., 2011).
For histological analysis, animals were anesthetized (as above) and
transcardially perfused with 4% paraformaldehyde (PFA) in phosphate
buffer (PB). Brains were postfixed with 4% PFA overnight, washed in
phosphate buffer, cryoprotected in a 30% sucrose solution, and, after
cutting, were stained according to a standard immunofluorescence pro-
cedure in 0.1 M PB for 48 h (Buffo et al., 2008; Boda et al., 2011). Adult
brains were cut into 30-m-thick coronal sections and collected in PBS.
Brain slices of postnatal pups (P5) were placed directly onto glass slides.
The sections were stained to detect the expression of different antigens:
Nogo-A (11C7, 1:10,000; Novartis Pharma), NgR1 (1:1000, Alomone;
1:400, R&D Systems), glial fibrillary acidic protein (GFAP) (1:1000;
Dako), doublecortin (DCX) (1:400; Santa Cruz Biotechnology), Vimen-
tin (1:200; Developmental Studies Hybridoma Bank), III-tubulin (1:
500; Sigma), brain lipid binding protein (BLBP) (1:500;Millipore),-gal
(1:10,000; Cappel), green fluorescent protein (GFP) (1:700; Invitrogen),
BrdU (1:250; Abcam), Ki67 (1:1000; Novacastra), Ph3 (1:100; Millipore
Biotechnology), mammalian achaete-schute homolog 1 (Mash1) (1:200;
BDPharmingen), and activated caspase 3 (1:150; Cell Signaling Technol-
ogy). Sections were incubated overnight with primary antibodies was
made overnight at 4°C in PBS with 1.5% donkey or goat serum and 0.5%
Triton X-100. Sections were then exposed for 2 h at room temperature to
secondary species-specific antibodies conjugatedwith Alexa Fluor 488 or Alexa
Fluor 546 (1:500; Invitrogen),Cy3 (1:500; Jackson ImmunoResearch), orAlexa
Fluor 649 (1:500; Invitrogen). Cell nucleiwere visualizedusing 4,6-diamidino-
2-phenylindole (DAPI; Fluka). After processing, sections were mounted
onmicroscope slides with Tris-glycerol supplemented with 10%Mowiol
(Calbiochem).
For detection of -gal, the high-sensitivity tyramide signal amplifica-
tion kit (PerkinElmer Life and Analytical Sciences) was used (Buffo et al.,
2008). This procedure was also applied for anti-NgR1 staining in the case
of double labeling with antibodies produced in the same species. To
facilitate BrdU recognition, slices were treated with 2NHCl for 20min at
37°C, followed by 10 min in borate buffer.
Neurosphere assay and explants. Adult SVZs were dissected and disso-
ciated, and cells (20,000 cells/ml) were cultivated in a standard neuro-
sphere assay (Pastrana et al., 2009). Treatments applied to the culture
medium included the following: anti-NgR1 (10 M; mNogo receptor
affinity-purified goat IgG; R & D Systems; Petrinovic et al., 2010;
Delekate et al., 2011) or control antibodies (goat anti-mouse IgG; Jack-
son ImmunoResearch), 11C7 or control antibodies, NEP1–40 (1 M;
Oertle et al., 2003) or vehicle solution, and Nogo-p4 peptide (4 M in
PBS; ADI Co.) (Wang and Zhu, 2008), or vehicle solution. In some cases,
primary spheres were dissociated and plated to generate secondary neu-
rospheres, which were then also treated with agonists or antagonists. In
other cases, only primary neurosphere were treated. Rate of neurosphere
generation was determined as the number of primary neurospheres/
number of viable seeded cells. Self-renewal was determined as the num-
ber of secondary neurospheres/number of viable seeded cells derived
fromprimary spheres. For assessment of differentiation, neurospheres as
a whole or as single-cell suspensions were plated in differentiation me-
dium for 7 d (Buffo et al., 2008). The number of viable cells was deter-
mined by trypan blue exclusion. Diameters of living neurospheres were
measured using NIS-Element software (Nikon).
Postnatal explants were prepared according toWichterle et al. (1997).
Tissues from the SVZ, RMS, and subependymal layer of the OB (SEL–
OB) were embedded in 75%Matrigel growth factor reduced (BD Biosci-
ences) and maintained for 1 d in vitro in Neurobasal medium
(Invitrogen) supplemented with B27 (1; Miltenyi), penicillin/strepto-
mycin (20U/ml; Sigma), and 0.5mM glutamine (Invitrogen). Antibodies
and compounds were mixed with Matrigel together with the Rho-
associated, coiled-coil containing protein kinase (ROCK) inhibitor Y27632
(4-[(1R)-1-aminoethyl]-N-pyridin-4-yl-cyclohexane-1-carboxamide) (10
g/ml; Sigma-Aldrich). Only vital explants with cells moving out of the
tissue core (80–90%of the total) were analyzed, with virtually all of these
cells emigrating in chains. In some experiments, explants were grown on
a monolayer of RMS-derived astrocytes according to García-Marque´s et
al. (2010). For analysis, explants were fixed in 4% PFA for 40 min and
stained. Vital staining to visualize surface Nogo-A was performed as
described previously (Mathis et al., 2010).
To test whether the highly inhibitory Nogo-A region Nogo-A–20
(Oertle et al., 2003) affects SVZ-derived cell adhesion, glass coverslips (1
cm2) were coated with poly-D-lysine (PDL) (5 g/ml), washed three
times, and subsequently coated with Nogo-A–20 (100 pmol, diluted in
PBS) for 1 h at 37°C. Unbound Nogo-A–20 was removed by three
washes with PBS. Adult SVZs were dissociated, and cells were either
plated on PDL only or Nogo-A–20-coated coverslips (12,000 cells/cm2
in DMEM/F-12 supplemented with B27). After 1 h, cells were fixed,
stained, and scored. The average number of adhered cells was determined
by counting in five randomly chosen fields of view of the coverslips.
Cell isolation and RT-PCR. Adult mouse SVZs were dissected from 10
to 20 animals and dissociated using Neural Tissue Dissociation kit
(Miltenyi). Polysialic acid–neural cell adhesion molecule-positive
(PSA-NCAM) neuroblasts or glutamate aspartate transporter (GLAST)-
expressing astrocytes were enriched by positive selection using antibody-
conjugated magnetic beads, according to the instructions of the
manufacturers (Miltenyi). A double round of selection was applied to
isolate GLAST cells (94% purity, anti-GLAST antibodies conju-
gated to allophycocyanin and detected by flow cytometry, FACSCanto;
BD Biosciences), whereas a single round yielded 90% purity for
PSA-NCAM cells (anti-PSA-CAM conjugated to phycoerythrin). Total
RNA was extracted from the cell fractions with the RNeasy micro
kit (Qiagen), and reverse transcribed to single-stranded cDNA with the
High-Capacity cDNA Archive kit (Applied Biosystems). cDNAs were
amplified in each PCR assay with Go TaqDNA Polymerase (2.5 U/sam-
ple; Promega) in a 25 l reaction mixture containing 1 M forward and
reverse primers, 0.2 mM dNTPs, and 1.5 mM MgCl2. Adult brain cDNA
was used as a positive control and negative controls lacking cDNAor Taq
polymerase were processed in parallel. Primers used were the following:
Nogo-A, forward, 5-TGAGGGAAGTAGGGATGTGC-3; reverse, 5-
CAGGTGATGTACGCTCTGGA-3 (183 bp); NgR, forward, 5-
ATCTTCCTGCATGGCAACCGAAT-3; reverse, 5-AGAGGTTGTTG
GCAAACAGGTAG-3 (531 bp); III-tubulin, forward, 5-ATCCAC
CTTCATTGGCAACAGCAC-3; reverse, 5-ACTCGGACACCAGGT
CATTCATGT-3 (173 bp); BLBP, forward, 5-TGAGTACATGA
AAGCTCTGGGCGT-3; and reverse, 5-TGAGCTTGTCTCCATC
CAACCGAA-3 (224 bp). Amplifications followed this protocol: 35 cy-
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cles, each cycle with 95°C for 30 s, 62°C for 1 min, 72°C for 30 s, after an
initial denaturation at 95°C for 3 min.
Image processing and data analyses.Histological specimens were exam-
ined using an E-800Nikonmicroscope connected to a colorCCDcamera
and a Leica TCS SP5 confocal microscope. All images were collected with
the confocal microscope. Adobe Photoshop 6.0 (Adobe Systems) was
used to adjust image contrast and assemble the final plates. Most quan-
titations were performed by confocal analysis. However, in some in-
stances, the Neurolucida software (MicroBrightField) was used. For
evaluation of cell densities or the number of cells per area per section or
the extent of labeling after in vivo injections and pump implantations,
comparisons were made between hemispheres ipsilateral to the injec-
tion/infusion site of control (ctrl) and treated animals (unless differently
stated). Measurements were derived from at least three sections per ani-
mal. Three to five animals were analyzed for each time point or experi-
mental condition. Number of animals (n) in text includes both treated
and control animals. For neurosphere experiments, data are derived
from at least three experiments. For explants analyses, 30 individual
explants were pulled for each experimental condition. For in vitro data, n
refers to a single experiment. Isolated or pyknotic cells were identified on
the basis of DAPI staining. Staining intensity and percentage of stained
areaswerequantifiedusingNIHImageJ software(http://rsb.info.nih.gov/
ij/). Statistical analyses were performed by SigmaStat software package
(Jandel Scientific) and included unpaired and paired Student’s t test,
one-wayANOVA, and 2 test. In all instances, p 0.05was considered as
statistically significant. Data are expressed as averages SEM.
Results
Nogo-A and NgR1 expression pattern in the adult and
postnatal SVZ–OB system
The expression patterns of Nogo-A and NgR1 in the SVZ–OB
system were assessed in coronal telencephalic sections of adult
and postnatal (P5) mice. In the adult brain, anti-Nogo-A and
anti-NgR1 immunostaining displayed a reciprocal expression
pattern and a clear segregation to distinct cell types (Fig. 1A, SVZ,
and A, RMS). Nogo-A antiserum labeled DCX neuroblasts
(Fig. 1B–D), whereas anti-NgR1 antibodies stained GFAP cells
(Fig. 1F–G). Quantitative analyses of confocal images through-
out the SVZ–OB system confirmed that the vast majority of neu-
Figure 1. Expression patterns of Nogo-A and NgR1 in the adult SVZ–OB system. A, A, Anti-Nogo-A and anti-NgR1 labeling appear complementary in both the DH–SVZ (A) and the RMS (A).
B–D, Nogo-A labeling identifies DCX-expressing neuroblasts in the DH–SVZ (B), RMS (C), and LW (D). E, Quantifications of Nogo-A and DCX coexpression in the SVZ–OB system (n 5). F–G, The
astrocyticmarker GFAP andNgR1 colocalize in germinal astrocytes.H, Quantification ofNgR1 andGFAP coexpression in the SVZ–OB system (n5). I–L, Absence of costaining for Nogo-A andGFAP,
or NgR1 and DCX. Error bars indicate SEM. Scale bars: A, A, F, F, I, J, 30m; B–D, K, I, 20m.
17790 • J. Neurosci., December 5, 2012 • 32(49):17788–17799 Rolando et al. • Roles of Nogo-A and NgR1 in Adult Neurogenesis
roblasts expressed Nogo-A and that all Nogo-A cells displayed
immature neuronal traits (Fig. 1E). Conversely, NgR1 was ex-
pressed by the vastmajority ofGFAP astroglial cells andNgR1
elements consistently displayed an astroglial phenotype (Fig.
1H). As additional evidence for the segregation of Nogo-A and
NgR1 to distinct cell types, no significant overlap of Nogo-A and
GFAP or NgR1 and DCX was detected by confocal and auto-
mated analyses (Figs. 1I–L, 2A,B). No evidence was found for
NgR1 expression in Mash1 transit amplifying cells (Fig. 2C).
To further confirm our immunohistochemical observations,
RT-PCRwas performed on adult SVZ cells selected bymagnetic-
activated cell sorting (MACS) on the basis of neuroblast (Peretto
et al., 2005) or astrocyte lineage (Ninkovic et al., 2007) surface
markers (PSA-NCAMandGLAST, respectively). Consistentwith
immunohistochemical data, Nogo-A or NgR1 transcripts are
highly enriched in the correspondent neuronal or astroglial frac-
tions (Fig. 2D). Moreover, postnatal (P5) brains displayed an
expression pattern fully consistent with that of the adult SVZ–OB
system (Fig. 2E–H). Thus, Nogo-A and NgR1 are reciprocally
expressed by neuroblasts and astrocytes in the adult andpostnatal
SVZ–OB system.
Pharmacological antagonization of NgR1 signaling increases
the rate of neurosphere formation and stimulates
proliferation
To shed light on the role(s) of the Nogo-A/NgR1 signaling in the
SVZ, we first evaluated the effects of Nogo-A/NgR1 pharmaco-
logical antagonization/activation on the capability of adult SVZ
progenitors to generate neurospheres in response to mitogens
(neurosphere assay; Reynolds and Weiss, 1992), an index of the
progenitor activation state (Pastrana et al., 2009).
To neutralize NgR1 activation attributable to binding of the
Nogo-66 domain, we applied the NEP1–40 peptide (Nogo-A ex-
tracellular peptide residues 1–40 amino acids of Nogo-66)
(GrandPre´ et al., 2002) or the NgR1 function blocking antibody
(Petrinovic et al., 2010; Delekate et al., 2011). Nogo-A–20 ac-
tivity was blocked by the specific 11C7 neutralizing antibody
(Oertle et al., 2003). In parallel experiments, NgR1 was activated
by treatments with Nogo-p4, the active segment of Nogo-66
(Wang and Zhu, 2008). NgR1 antagonization by both peptide
and antibody treatments increased the rate of primary neuro-
sphere generation by 1.6-fold compared with control cultures at
7 d in vitro (Fig. 3A,B,D). Furthermore, NgR1 antagonization
significantly augmented the size of primary neurospheres with
respect to controls, indicating enhanced proliferation (Fig.
3A,B,E). Conversely, when NgR1 was activated by Nogo-p4, we
observed a remarkable decrease in both the number and the di-
ameter of neurospheres (Fig. 3A,C,D,E). Notably, 11C7 anti-
body treatment did not faithfully reproduce the effects of NgR1
neutralization (rate of neurosphere generation, ctrl, 100 
13.3%; 11C7, 111.1 40.1%; p 0.81; diameter, ctrl, 78.9 8.9
m; 11C7, 79.3  22.1 m; p  0.98), suggesting that the 20
domain ismuch less effective than theNogo-66 loop in regulating
the function of SVZ progenitors. When the outcomes of NgR1
antagonization or activation were tested on secondary neuro-
sphere generation, the effects of both treatmentswere remarkably
amplified (Fig. 3F). Furthermore, overall the effects were main-
tained over three passages even when only primary neurospheres
were treated (data not shown), indicating that NgR1 is potently
acting on mechanisms that control self-renewal.
Neurosphere cells always maintained the capability to differ-
entiate along all the three neural lineages (data not shown), re-
vealing unaltered multipotency. Altogether, these in vitro results
point to a role forNgR1-mediated signals in restricting activation
and proliferation of adult SVZ progenitors.
NgR1 antagonization expands the SVZ NSC pool by cell
proliferation in vivo
Starting from these in vitro findings, we investigated the role of
Nogo-66-to-NgR1 signaling in the SVZ in vivo. To visualize
NSCs, we used adult hGFAP::GFP mice (Zhuo et al., 1997), in
which SVZNSCs are highlighted byGFP expression driven by the
Figure 2. A, Quantification of anti-GFAP and anti-Nogo-A immunostaining colocalization in the adult SVZ–OB system by automatic pixel analysis. B, Anti-NgR1 and anti-DCX immunostaining
overlap coefficient in the SVZ–OB system. C, NgR1-expressing cells do not coexpress Mash1. D, RT-PCR analysis on MACS-sorted PSA-NCAM or GLAST cells reveals distinct expression levels for
Nogo-A and NgR1 in these cell types. E–H, Expression patterns of Nogo-A and NgR1 in the postnatal SVZ. Nogo-A cells express DCX (E) but are negative for the astrocytic marker BLBP (F ).
Conversely, NgR1 cells donot costain for theneuronal proteinIII-tubulin (G) but express the astroglialmarker vimentin (H ). Error bars indicate SEM. Scale bars:C, 50m;E, 40m;F,G, 20m;
H, 30m.
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human GFAP (hGFAP) promoter (Doet-
sch et al., 1999a). We injected the
NEP1–40 peptide or vehicle solution in
the lateral ventricles and investigated
whether NgR1 inhibition affected NSC
number and proliferation at 3 d after
treatment (Fig. 4A). BrdU intraperito-
neal injection was used to monitor NSC
proliferation. In the peptide-treated
hemispheres, the number of GFP cells
was increased compared with controls
in both the dorsal horn (DH)–SVZ (Fig.
4B–D, 1.6-fold increase) and the LW
(Fig. 4E–G, twofold increase). More-
over, the high-density cellular layer
underneath the ventricular surface dis-
played a 1.6-fold thickening (Fig. 4H ).
Notably, although in controls we hardly
detected any GFP/BrdU cells, they
were much more frequent during
NEP1–40 administration (2.8-fold in-
crease; Fig. 4I–M ) and included numer-
ous mitotic figures (Fig. 4J ).
To examine the progeny of NSCs at
this time point, we repeated the same ex-
periment using GLAST::CreErt2;R26R
mice (Mori et al., 2006), in which a cohort
of NSCs expresses-gal during tamoxifen
administration (Fig. 5A) and inherits re-
porter gene expression in its derivatives
(Ninkovic et al., 2007). Consistent with the results obtained with
the hGFAP::GFP line, in NEP1–40-treated animals, we observed
a significant thickening of the LW (ctrl, 13.3  0.2 m; NEP1–
40, 20.5 1.3m; p 0.01; n 6) and a marked increase in the
number of -gal cells that were mostly positive for GFAP (Fig.
5B–G). In addition,-gal/Mash1 transit amplifying cells were
moderately increased (1.5-fold), suggesting that the immediate
NSC progeny was just starting to expand (Fig. 5H, I). NEP1–40
treatment had no effect on DCX derivatives (Fig. 5J–M). These
data are consistent with the early phases of a primary effect of
NgR1 antagonization on the activation and proliferation of SVZ
NSCs. They further suggest that, via interaction with NgR1,
Nogo-A expressed by neuroblasts exerts a negative feedback on
NSC proliferation, thereby limiting the pace of neurogenesis. To
test this hypothesis, we induced a massive accumulation of neu-
roblasts at the SVZ by altering CP signaling (Sawamoto et al.,
2006) over 2 weeks (Fig. 5N,O) and found a remarkable reduc-
tion of DH–SVZ-gal/BrdU/DCX-negative cells (Fig. 5P,R),
consistent with a negative control exerted by new neurons on
NSC proliferation. Importantly, this decrease was reverted to
control values by NEP1–40-mediated disruption of Nogo-A/
NgR1 interaction (Fig. 5P,Q,S), showing an inhibitory action of
NgR1 on NSCs. Similar effects were observed at the LW (ctrl,
1.6  0.3 -gal/BrdU/DCX-negative cells/mm; CP no cells,
CP NEP1–40, 1.7 0.3 cells/mm; n 10; one-way ANOVA,
F(2,7) 11.07, p 0.07, post hocTukey’s test; ctrl vs CPNEP1–
40, p  1.00; ctrl vs CP, p  0.013, CP vs CP  NEP1–40,
p 0.09).
NgR1 antagonization increases neurogenesis in vivo
To further understand whether interfering with NgR1 signaling
modifies the neurogenic capability of NSCs, NEP1–40 or vehicle
solutions were chronically infused in the lateral ventricles for 1
week via osmotic minipumps (Fig. 6A). In NEP1–40-treated
hemispheres, GFAP-expressing cells were packed along both the
LW and DH–SVZ (Fig. 6B,D,D), and the SVZ layers appeared
thickened (Fig. 6C,D), consistent with a persistent activation of
NSCs. At this time point, the number of -gal/DCX cells was
also greatly expanded in the DH–SVZ (Fig. 6E–G, 1.98-fold in-
crease), suggesting that the protracted treatment enhanced neu-
rogenic activity of the enlarged pool of SVZ NSCs. These results
could also be attributable to the reduced emigration of -gal/
DCX cells from the SVZ.However, this possibility was excluded
because the number of -gal/DCX cells in the RMS was un-
changed (NEP1–40, 1680.1 150.8 cells/mm2 vs ctrl, 1405.1
180 cells/mm2, p  0.81, n  8), and the RMS maintained its
normal organization and size (Fig. 6H, I). To further substantiate
this point, we treatedwild-typemice and injected a single pulse of
BrdU intraperitoneally at the moment of minipump implanta-
tion to tag cells either exiting the cell cycle at the beginning of
treatment (thereby maintaining high levels of BrdU) or continu-
ing to cycle over the week (thereby diluting the BrdU). The den-
sity of BrdU nuclei was markedly increased in the DH–SVZ
(Fig. 6L–N), andmost of these cells wereDCX neuroblasts (Fig.
6L,M). By selecting strongly BrdU-immunolabeled nuclei, we
quantified elements that became postmitotic at the beginning of
the treatment and should have moved toward the OB. However,
no differences were found in the ratio between strongly BrdU-
labeled neuroblasts (sBrdU/DCX cells) in the RMS and DH–
SVZ of NEP1–40- and vehicle-infused mice (ratio NEP1–40
RMS/SVZ, 1.9 0.5 vs ctrl, 1.3 0.3, p 0.36; sBrdU/DCX
cells, DH–SVZ, NEP1–40, 532.9  70.3 DCX/sBrdU cells/
mm2 vs ctrl, 377.1  37.8 DCX/sBrdU cells/mm2; RMS,
NEP1–40, 680.5  81.7 DCX/sBrdU cells/mm2 vs ctrl,
505.4  81.1 DCX/sBrdU cells/mm2, n  8), showing that
NgR1 inhibition did not impair neuroblast progression to the
Figure 3. Neurosphere assay during NgR1 antagonization or activation. A–C, Micrographs depict neurospheres produced in
control condition (A) and after NEP1–40 (B) or Nogo-p4 exposure (C). D, Quantification of the rate of primary neurosphere
generation at 7 d of NgR1 blockade (by either NEP1–40 or anti--NgR1 treatment; ctrl vs NEP1–40, p 0.005, n 4; ctrl vs
anti-NgR, p 0.021, n 3, paired t test) or of activation by Nogo-p4 (ctrl vs p4, p 0.015, n 3, paired t test). Because no
differences were detected among distinct controls ( p 0.29, n 4), data were pooled together. E, Primary neurosphere size
increases after NgR1 antagonization,whereas it is reducedwhenNgR1 is activated (ctrl vs NEP1–40, p 0.011; ctrl vs anti-NgR1,
p 0.013; ctrl vs Nogo-p4, p 0.027, n 3). F, The rate of secondary sphere formation is greatly enhanced when NgR1 is
antagonized, although it is strongly reduced by the Nogo-p4 NgR1 activator. NS, Neurospheres. Paired t test: *p 0.05, **p
0.01. Error bars indicate SEM. Scale bars, 100m.
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OB. This result was further corroborated by experiments on SVZ
explants (see below).
Parallel analysis of neuroblasts displaying low levels of BrdU,
indicative of more recent generation, yielded increased numbers
in the NEP1–40-treated DH–SVZ (NEP1–40, 2571  233.2
BrdU cells/mm2 vs ctrl, 1400.8 62.8 BrdU cells/mm2, p
0.008, n 6). Among such neuroblasts, Ki67 actively dividing
cells were also expanded during NgR1 inhibition (Fig. 6O,P, 1.9-
fold increase of Ki67/DCX cells; NEP1–40, 2328.2  259.9
cells/mm2 vs ctrl, 1226.5 143.5 cells/mm2). This phenomenon
was proportional to a global enhancement of active proliferation
(Fig. 6O,P, 1.9-fold increase of Ki67 cells; 3910  303 cells/
mm2 in the DH–SVZ in NEP1–40-treated animals vs 2018.5 
420.3 cells/mm2 in controls, p 0.05), consistent with an incre-
mented neurogenesis sustained by general stimulation of SVZ
functioning.
The finding that such an incremented neurogenesis is not
reflected by an enlargement of the RMS size raises the possi-
bility that part of the newly generated neuroblasts undergo
apoptosis while progressing rostrally. However, we found no
evidence of enhanced apoptosis, as detected by anti-active
caspase staining (ctrl, 0.5  0.1 cells/SVZ–LW, NEP1–40,
0.6  0.2 cells/SVZ-LW, p  0.29; RMS, ctrl, 0.3  0.2 cells/
RMS, NEP1–40, 0.2 0.1 cells/RMS, p 0.32) and inspection
of pyknotic nuclei (ctrl, 0.9  0.1 cells/SVZ-LW, NEP1–40,
0.7  0.01 cells/SVZ-LW, p  0.78; RMS, ctrl, 0.7  0.03
cells/RMS, NEP1–40, 0.6 0.2 cells/RMS, p 0.81). Further-
more, at longer survival times, we did observe an increased
Figure 4. NgR1 antagonization in adult hGFAP::GFP mice. A, Experimental design. B, C, E, F, During NgR1 antagonization (C, F ), the number of GFP cells increases compared with vehicle
administration (B,E) in both theDH–SVZ and LW.D,G, GFP cells after NEP1–40 treatment in theDH–SVZ (D) and LW (G) (DH–SVZ, p 0.027; LW, p 0.042, unpaired t test,n 6).H, Increase
in the thickness of the high-density layer underneath the ventricular surface in NEP1–40-treated mice ( p 0.024, unpaired t test, n 6). J, K, Examples of GFP/BrdU double-labeled cells
(arrowheads) in vehicle-treated (I ) and NEP1–40-treated (J, K ) animals. L,M, Quantification of GFP/BrdU double-expressing cells in the DH–SVZ (L) and LW (M ) (DH–SVZ, p 0.023; LW, p
0.015, unpaired t test, n 6). Unpaired t test: *p 0.05. Error bars indicate SEM. Scale bars: B, C, 50m; I–K, 10m; E, F, 20m.
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cellularity and an expansion of the RMS (Fig. 6 J,K; ctrl,
10,178.4  867.3 m2 vs NEP1–40, 14,825.3  1226.8 m2,
p 0.03, n 6), indicating that, after 1 week of treatment, the
bulk of newly produced cells had not yet reached more rostral
sites. Together, these results reveal a role for NgR1-mediated
signals in the regulation of SVZ NSC neurogenesis.
Nogo-A–20 supports the migration of SVZ–RMS
neuroblasts independently of NgR1 in vitro
To unveil additional roles of Nogo-A/NgR1 signaling in SVZ–OB
neurogenesis, we used postnatal explants of the SVZ, RMS, and
SEL–OB as an in vitromodel to investigate neuroblast migration
toward the OB. Nogo-A neuroblasts move out of the explant
core by chainmigration, as occurs in the RMS in vivo (Fig. 7A,B)
(Wichterle et al., 1997). Treatment with 11C7 to inhibit Nogo-
A–20 (Fig. 7C–E) induced a reduction of the areas of neuroblast
migration that was more pronounced with increasing antibody
concentrations (Fig. 7F). Both SVZ and RMS explants displayed
smaller migration areas compared with controls (Fig. 7C–E),
whereas no reduction was observed in SEL–OB explants, indicat-
ing different effects of Nogo-A signaling on tangential (RMS) or
radial (OB)migration. Importantly, reduction ofmigratory areas
Figure 5. NgR1 neutralization in adult GLAST::CreErt2;R26Rmice. A, Experimental design. Tam, Tamoxifen.B–E,-gal/GFAP cells in the DH-SVZ (B, C) and LW (D, E) of vehicle-treated (B,
B,D) andNEP1–40-threated (C,C,E) animals.F,G, Quantificationsof-galand-gal/DCX cells perDH–SVZ (F ) or LW(G) per sectionduringNgR1antagonization (DH–SVZ,-gal cells,
p 0.001;-gal/DCX cells, p 0.25; LW,-gal cells, p 0.048;-gal/DCX cells, p 0.11, unpaired t test, n 6). H, I, Images illustrate the increase in-gal/Mash1 cells
(arrowheads) duringNgR1 antagonization in the LW. J–M, Pictures illustrate the increase in-gal-expressing cells after NEP1–40 administration in the DH–SVZ (J,K ) and LW (L,M ).Most of these
cells do not express DCX. N, Grafting of CP and NEP1–40 injection: experimental design. O–S, When CP is grafted rostrally along the RMS (O, arrowheads), neuroblasts accumulate at the SVZ
(compare R, ctrl intact, and Q, CP grafted) and proliferation of -gal/DCX-negative cells (yellow arrowheads, see insets) decreases at the DH–SVZ (P). However, NEP1–40 injection reverts
proliferation to control values (P; one-way ANOVA, F(2,7) 8.9, p 0.016, n 10; post hoc Tukey’s test, ctrl vs CP, p 0.019; ctrl vs CPNEP1–40, p 0.88; CP vs CPNEP1–40, p 0.03),
despite persisting neuroblast amassing (S). Unpaired t test: *p 0.05, **p 0.01. Error bars indicate SEM. Scale bars: B–E, 20m; J, K, Q–S, 30m; L,M, 15m; H, I, 10m; O, 100m.
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was not attributable to cell death (number of pyknotic nuclei
was unaltered; ctrl, 0.3 0.1% vs 11C7, 0.4 0.04%, p 0.6)
or to decreased production of neuroblasts by diminished pro-
liferation (Fig. 7G). Visual inspection and quantification of
the number of isolated cells (ctrl, 0.2  0.1% vs 11C7, 0.3 
0.2%, p 0.7, n 4) revealed that cell chains were preserved,
although 11C7 treatment increased the frequency of shorter
chains (Fig. 7H; 13
2  115.5, p  0.0001, n  455). These
results suggest that Nogo-A–20-driven signals support the
tangential migratory capacity of neuroblasts but are not im-
plicated in chain formation.
Some astrocytes can alsomove from the explant to thematrix,
in which they might promote neuroblast migration through
paracrine and/or contact-mediated mechanisms, including
Nogo-A/NgR1 interactions. To test this hypothesis, we exposed
explants to NgR1 antagonists (anti-NgR1 antiserum and NEP1–
40), but no changes in neuroblast migration were observed (Fig.
7I–K), even when the explants were plated on RMS astrocyte
monolayers (García-Marque´s et al., 2010) to better mimic in vivo
conditions (Fig. 7L–M; NEP1–40 vs ctrl, SVZ, 96.6  7.2%,
100 18.2%, p 0.87; RMS, 117.2 15.2%, 100 10.7%, p
0.52, n  3). Thus, consistent with in vivo observations, NgR1
signaling is not involved in neuroblast migration.
Nogo-Amigratory function is mediated by ROCK signaling
and anti-adhesive effects
Whereas the Nogo-66 sequence binding to NgR1 is present in all
the three major Nogo isoforms (Nogo-A–Nogo-C), Nogo-A
interacts with an additional receptor (subunit) that is not yet
characterized (Schwab, 2010). Our data indicate that this Nogo-
A-specific receptor, and not NgR1, influences neuroblast migra-
tion. Notably, the effects of Nogo-A–20 as well as those of
Nogo-66 are known to operate through the activation of the GT-
Pase RhoA and its effector protein ROCK (Petrinovic et al., 2010;
Schwab, 2010). To assess whether this pathwaymediates Nogo-A
action in neuroblast migration, we applied the ROCK pharma-
cological inhibitor Y27632 (Petrinovic et al., 2010) on SVZ and
RMS explants. After treatment, we observed a dramatic decrease
in cell migration (Fig. 7N–Q).
To clarify whether Nogo-A could operate through intracellu-
lar pathways other than ROCK activation, we compared the ef-
fects of ROCK inhibition with those of simultaneous application
of both ROCK inhibitor and 11C7. The latter experimental con-
dition resulted in a significant decrease in migratory areas, but
this effect was not different from Y27632 alone (Fig. 7N,O).
These data show that Nogo-A action on neuroblast migration is
exclusively mediated by the classical ROCK signaling cascade. In
Figure 6. ChronicNgR1 inhibition inadultGLAST::CreErt2;R26Randwild-typemice.A, Experimental design.B, Expansionof theareaalong theLW labeled forGFAPafterNgR1antagonization (p0.022,
unpaired t test, n 8). C–D, Anti-GFAP staining increases in the LW (D) and DH–SVZ (D) of NEP1–40-treated animals. E, F, H, I, Micrographs depict-gal/DCX-expressing cells in control (E, H ) and
NEP1–40-treated(F, I )animalsat7dofsurvival. J,K, Images illustratetheRMSofcontrol (J )andNEP1–40-treated(K )animals10dafter startingthetreatment.G,AfterNEP1–40administration, thenumber
of these cells augments in the DH–SVZ (p 0.006, unpaired t test, n 6). L,M, Pictures illustrate cells with strong (arrowheads) or low (arrows) BrdU staining in the DH–SVZ of vehicle-treated (L) and
NEP1–40-treated(M )mice.L,M,BrdU/DCXcells intheDH–SVZincontrol (L)andNgR1antagonizedmice(M).N,QuantificationofBrdUcell increase intheDH–SVZafterNgR1antagonization(p
0.012,unpaired t test,n8).O,P, Representative imagesofKi67-andDCX-expressingcells in theDH–SVZofvehicle-treated(O)andpeptide-treated(P)animals.Unpaired t test: *p0.05,**p0.01.Error
bars indicate SEM. Scale bars: C, C,O,P, 20m;H, I, 30m;D,D, 35m; J,K, 45m; E, F, L,M, 50m.
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addition, our observations indicate that the Nogo-A–20 effect
on neuroblast migration is NgR1 independent and likely causes
the activation of an unidentified receptor, which operates
through the ROCK pathway. This intracellular effector could
promote cell migration by regulating the balance between cell
adhesion and repulsion. We therefore assessed the adhesiveness
of adult SVZ-derived cells to a Nogo-A–20-coated substrate. In
this condition, III-tubulin cells were less able to adhere to
coverslips compared with when they were plated on PDL-coated
glass (III-tubulin cells per field; PDL, 13.2  0.42; Nogo-A–
20, 5.6 0.76, p 0.001,n 3). Together, our data suggest that
Nogo-A provides anti-adhesive signals, thus promoting neuro-
blast progression and sustaining their migration.
Nogo-A–20 domainmediates neuroblast migration in vivo
To confirm in vivo the role of Nogo-A–20 in neuroblast migra-
tion, 11C7 neutralizing antiserum or control antibodies were in-
fused intraventricularly by osmotic minipumps for 7 d in adult
mice (Fig. 8A). A pulse of BrdU was administered at the time of
minipump insertion. As for Nogo-66-NgR1 antagonization,
these experiments were performed in both GLAST::CreERT2;
R26R and wild-type mice. In agreement with an effect distinct
from that of direct NgR1 inhibition (see above), but in line with
in vitro data on neurosphere formation, no significant changes
were observed inGFAP expression (Fig. 8B,C; ctrl, 1.17 0.45%;
11C7, 1.13 0.16%, p 0.91, n 6), SVZ thickness (ctrl, 8.61
1.16 m; 11C7, 10.9  2.92 m, p  0.43, n  6), or mitotic
activity (Ki67 cells; 11C7, 2144.5  267 cells/mm2 vs ctrl,
1987.5  135.3 cells/mm2, p  0.87, n  6). However, 11C7
application triggered an approximate threefold reduction in the
ratio between-gal/DCX cells in the RMS or SVZ (Fig. 8D–F;
ratio RMS/SVZ, 11C7 vs ctrl -gal/DCX cells, DH–SVZ,
11C7, 2005.3 41.5 cells/mm2; ctrl, 1075.9 158.2 cells/mm2;
RMS, 11C7, 1055.7 143.6 cells/mm2; ctrl, 1412.2 248.5 cells/
mm2). These data are consistent with an amassing of neuroblasts
in the SVZ determined by reduced migration to the OB. To fur-
ther corroborate this conclusion, DCX cells with strong BrdU
labeling, i.e., those born at the beginning of the treatment (see
above), were quantified in wild-type animals. Nogo-A–20 neu-
tralization markedly reduced the ratio between DCX/BrdU
cells that had reached the RMS or remained the SVZ (Fig.
8G,H,K; DH–SVZ, 11C7, 435  49.9 vs ctrl, 252.3  71.8
BrdU/DCX/mm2; RMS, 11C7, 320.2 50.1 vs ctrl, 574 9.9
BrdU/DCX/mm2), showing an inhibition of neuroblast pro-
gression toward the OB. No cell spreading out of the SVZ/RMS
territories indicative of altered chain formation or disruption of
glial tubes was observed (Fig. 8G–J).
Finally, to rule out the possibility that increased proliferation
could contribute to cell accumulation in the SVZ, we quantified
DCX/Ki67 cells and found no change in neuroblast prolifer-
ation (DH–SVZ, 11C7 DCX/Ki67, 1506.5 200.5 cells/mm2
vs ctrl, 1477.9  110.9 cells/mm2, p  0.91, n  9). Although
these data clearly show that Nogo-A promotes neuroblast mobi-
lization via its 20 domain, they also indicate that DCX cell
accumulation attributable to 7 d of 11C7 treatment does not
reduce SVZ activity, as could be expected by the Nogo-A-
dependent inhibition found during CP grafting. This suggests
Figure 7. Nogo-A andNgR1 inhibition in SVZ-OB explants.A,B, Micrographs showNogo-A cells (A) that express DCX in SVZ-OB explants at 1 d in vitro. C, Quantification of the decrease in themigration
areasof 11C7exposedexplants versus controls (SVZ, ctrl vs 11C7,p0.012,n5;RMS, ctrl vs 11C7,p0.008,n4;OB, ctrl vs 11C7,p0.218,n4, paired t test).D,E, Examplesof reducedneuroblast
migrationafter 11C7 treatment.F, Analysis ofneuroblastmigrationareasat increasing concentrationsof 11C7 (50ng/ml,p0.59; 100ng/ml,p0.036; 0.5g/ml,p0.030;n3).G, NumberofPh3
cells in control and 11C7-treated explants (SVZ, RMS, p	 0.05, n 3). H, Quantification of the distance from the explant core of neuroblasts moving in chains in 11C7-treated or control explants. I, J,
Representative images of control (I ) and NgR1 antagonized (J ) explants at 1 d in vitro. K, Quantification shows no changes in the migration areas in NgR1-antagonized explants compared with controls
(anti--NgRvsctrl,SVZ,p0.89;RMS,p0.79;OB,p0.52,n5;NEP1–40vsctrl,SVZ,p0.91;RMS,p0.67;OB,p0.61;n3).L,M,NgR1antagonizationdoesnotchangeneuroblastmigration
areaswhenexplants are platedona feeder layer of RMSastrocytes (NEP1–40vs ctrl, SVZ, 96.67.2%,10018.2%,p0.87; RMS, 117.215.2%,10010.7%,p0.52;n3).N,O, Quantification
of the decrease in themigration areas duringROCK inhibition (J, SVZ, ctrl vs Y27632,p0.003; ctrl vs 11C7Y27632,p0.004; SVZ, Y2763211C7 vs Y27632,p0.31, unpaired t test,n4;K, RMS,
ctrl vs Y27632, p 0.009; ctrl vs 11C7 Y27632, p 0.03, unpaired t test; RMS, Y27632 11C7 vs Y27632, p 0.42; n 4). P, Q, Neuroblast emigration from explants during ROCK blockade.
Unpaired t test: *p 0.05, **p 0.01, ***p 0.0001. Error bars indicate SEM. Scale bars:A,B, 50m;D, E,G–J, 100m;P,Q, 40m.
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thatNogo-Amediated reduction ofNSC activity builds up slowly
and requires	7 d to become overtly detectable.
Discussion
Nogo-A and its receptor NgR1 are master regulators of CNS
plasticity that physiologically restrict structural remodeling and
hamper axon regeneration during injury. Here we provide the
first evidence that Nogo-A/NgR1 signaling is implicated in an-
other form of neuroplasticity, namely neurogenesis in the adult
SVZ. We find that neuroblast-mediated Nogo-A signaling re-
stricts NSC proliferation through the activation of NgR1. In this
way, the rate of neuronal neogeneration can be dynamically ad-
justed according to the quantity of actually produced neurons. In
addition, we show that Nogo-A promotes the tangential migra-
tion of neuroblasts toward the OB, independent of NgR1. Alto-
gether, our observations point to a dual mechanism wherein
newly generated neuroblasts use Nogo-A signaling to modulate
neurogenic processes in the SVZ, while promoting their own
emigration toward the OB.
Nogo-A/NgR1 signaling regulates NSC function
Many intrinsic mechanisms and environmental factors regulate
neurogenic processes in the SVZ–OB. Based on the evidence that
depletion ofNSCderivatives stimulatemitotic activity ofNSCs, it
was hypothesized that neuroblasts inhibit NSC proliferation in
physiological conditions (Doetsch et al., 1999b), but the under-
lying molecular mediators are essentially unknown. Here, we
provide insights into this mechanism by showing that the
Nogo-66 domain of Nogo-A expressed by neuroblasts negatively
feeds back toNgR1NSCs to limit their activation, proliferation,
and self-renewal. A negative action on primary progenitors has
also been proposed previously for the neurotransmitter GABA
released by neuroblasts, whose levels in the extracellular space
canmodulateNSC proliferation according to the amount of neo-
generated neurons (Liu et al., 2005). In addition to soluble sig-
nals, however, regulation of NSC functionmay also exploit direct
cell-to-cell interactions. Eph/ephrin signaling could mediate
such a contact effect, because interfering with this pathwaymod-
ifies NSC proliferation (Conover et al., 2000; Ricard et al., 2006).
Nonetheless, the cellular distribution of these molecules in the
SVZ is unclear, and their positive or negative effect on NSC pro-
liferation is still uncertain. Therefore, it is difficult to unequivo-
cally identify Eph/ephrin as molecular mediators of a negative
feedback loop exerted by neuroblasts on NSCs. Direct interac-
tions between neural precursor cells and NSCs have instead been
implicated in the Notch-dependent reduction of NSC number
and self-renewal triggered by epidermal growth factor receptor-
mediated expansion of the NSC progeny (Aguirre et al., 2010).
However, the molecular interactors acting in this cell-to cell in-
terplay remain to be fully understood. In our study, a clear con-
tact inhibition operating through Nogo-66/NgR1 interactions
emerges. Grafts of CPs along the RMS arrest neuroblast migra-
tion and induce the accumulation of neogenerated neurons in the
SVZ (Sawamoto et al., 2006), which is associated with a signifi-
cant decrease ofNSCproliferation.Most importantly, disruption
of Nogo-66/NgR1 interaction completely reverses this effect,
highlighting the prominent role of cell-to-cell contact.
Nogo-A/NgR1-mediated inhibition on NSCs would be re-
leased as neuroblasts emigrate away or die, thus allowing reacti-
vation of neurogenesis. Notably, neuroblast emigration toward
the OB is promoted by Nogo-A itself via the interaction of the
Nogo-A–20 domain with an uncharacterized receptor ex-
pressed by neogenerated neurons (see below). Hence, our results
indicate a dual role for Nogo-A. On the one hand, through dis-
tinct transduction machineries, Nogo-A inhibits progenitor am-
plification, but on the other hand favors the release of its own
inhibition by promoting neuroblast emigration from the SVZ. To
our knowledge, such a mechanism of action is unique among
known modulators of germinal niche activity and appears most
suited to regulate the rhythm of neurogenesis in the SVZ accord-
ing to the number of actually produced neurons.
The molecular pathways associated with NgR1 activation in
SVZ NSCs are still undefined. Notch signaling appears to be a
promising candidate. Known as a key regulator of NSC prolifer-
ation and self-renewal, it is inhibited by expansion of NSC deriv-
Figure8. ChronicNogo-A inhibition inadultGLAST::CreErt2;R26Randwild-typemice.A, Experimental design.B,C, Anti-GFAP immunostainingof theLWincontrol conditionsandafter 11C7 treatment.D,
E,-gal/DCX cells in the DH–SVZ of control and 11C7 animals. F, Ratio of-gal/DCX cell densities in the RMS and DH–SVZ of control and treated mice (p 0.038, unpaired t test, n 7). G–J,
MicrographsshowaccumulationofBrdU/DCXcells intheDH–SVZof11C7-treatedanimalsandtheirdecreaseinnumberintheRMS.K,RatioofBrdU/DCXcelldensities intheRMSandDH–SVZofcontrol
and treatedmice (p 0.002, unpaired t test,n 9). Unpaired t test: *p 0.05, **p 0.01. Error bars indicate SEM. Scale bars:B, C, 10m;D, E, 40m; I, J, 30m.
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atives (Hitoshi et al., 2002; Alexson et al., 2006; Aguirre et al.,
2010) and regulates embryonic neurosphere formation after neu-
tralization of Nogo-66–NgR1 interactions (Lo¨o¨v et al., 2012). In
addition, the gap junction components Connexins sustain pro-
genitor proliferation (Miragall et al., 1997) and may be inhibited
by NgR1 activation (Wang et al., 2011). Finally, the possible con-
tribution of additional ligands of NgR1, such as Nogo-B and
Nogo-C (Schwab, 2010), also remains to be explored.
Nogo-A supports neuroblast migration through the
activation of Rho/ROCK pathway
The reciprocal expression pattern of Nogo-A in neuroblasts mi-
grating along the RMS andNgR1 in the surrounding astrocytes of
the glial tubes, prima facie, suggests a possible role for their inter-
action in the migratory process. However, this possibility is ex-
cluded by the lack of effects on cell migration, chain formation,
and RMS organization after NgR1 antagonization in vivo or in
vitro. Conversely, blockade of the Nogo-A–20 domain reduces
tangential migration, indicating that this process is modulated by
homotypic interactions between neuroblasts and disclosing dis-
tinct functions for the amino-Nogo and Nogo-66 domains.
Nogo-A–20 neutralization does not overtly impair chain
formation or disrupt the RMS structure, indicating that mecha-
nisms underlying reciprocal recognition and adhesion among
neuroblasts are preserved. Rather, the observation that Nogo-A–
20 coating repels neuroblasts suggests that the 20 domain
promotes cell-to-cell detachment to facilitate the effective sliding
of neuroblasts onto each other. We also show that the Nogo-A–
20 effects on migration involve the intracellular Rho/ROCK
pathway, a potent regulator of cytoskeleton dynamics and a com-
mon downstream effector of Nogo receptor-mediated functions
(Schwab, 2010). Collectively, these data suggest that Nogo-A–
20 supports tangential migration by modulating cell-to-cell
adhesion possibly through cytoskeleton reorganization. Further-
more, they show that an uncharacterized receptor (subunit), dis-
tinct from NgR1, mediates Nogo-A–20 functions in SVZ
neuroblasts.
These findingsonneuroblastprogression to theOBare ingeneral
agreementwith previous studies showing thatNogo-A regulates cell
motility, adhesion, andmigration of neuronal precursors in the de-
velopingcortex (Oertle et al., 2003;Mingorance-LeMeuret al., 2007;
Mathis et al., 2010).However, althoughour observations are consis-
tentwith thepositive effect ofNogo-Aon the tangentialmigrationof
early-born interneurons from the medial ganglionic eminence
(Mingorance-LeMeur et al., 2007), they donotmatch the enhanced
migration/motility observed in cells from Nogo-A knock-out mice
(Mathis et al., 2010) and during Nogo-A/NgR1 neutralization
(Oertle et al., 2003).Thesediscrepancies are likely related todifferent
migratory systems, each of which may be endowed with specific
regulatorymechanisms.Weare in fact comparinghomotypic sliding
of SVZ neuroblasts onto each other (chainmigration), interneuron
movements along corticofugal axons (Mingorance-Le Meur et al.,
2007), migration along radial glia scaffolds (Mathis et al., 2010),
and in vitromovements of single cells on substrates (Oertle et al.,
2003;Mathis et al., 2010). For instance, NgR1 activation does not
promotemigration in the RMS, but it effectively reducesmotility
of forebrain-derived precursors (Mathis et al., 2010). Interest-
ingly, Nogo-A–20 loses its promoting function when neuro-
blasts reach the SEL–OB and switch from tangential chain
migration to radialmovement along vascular scaffolds (Bovetti et
al., 2007). Thus,Nogo-A function in cellmigration varies accord-
ing to themolecular and cellular substrates interacting in distinct
migratory systems.
In conclusion, we show here that Nogo-A contributes to the
control of SVZhomeostasis by a dualmechanism (Fig. 9), involv-
ing distinct signaling domains. Heterotypic contact interaction
between neuroblasts and NSCs negatively regulates mitotic rates
to adjust the rhythm of neuronal neogeneration. Coincidentally,
homotypic interaction among neuroblasts favors tangential mi-
gration and releases NSCs from feedback inhibition.
Figure9. AdultSVZneurogenicnicheanditsmodulationbytheNogo-A/NgR1interaction.A,AttheleveloftheLWofthelateralventricle,NSCsdividetogeneratetransitamplifyingprogenitors(TAPs),which,
in turn, give rise toneuroblasts.B, TheNogo-66domainonneuroblastmembranes interactswithNgR1NSCsand limits both their proliferationandneurogenic activity. Conversely, theN terminal ofNogo-A,
containing the20domain, regulates neuroblastmigration through the interactionwith anuncharacterizedmediator that leads to the activation of the Rho/ROCKpathway.
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